CLGN logo

CLGN Stock Overview

Profile

Full Name:

CollPlant Biotechnologies Ltd.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

January 31, 2018

Indexes:

Not included

Description:

CollPlant Biotechnologies focuses on developing innovative medical solutions using plant-based collagen. Their products aim to improve healing and tissue regeneration, particularly in wound care and surgery. The company combines biotechnology and regenerative medicine to create advanced treatments for various medical needs.

Key Details

Price

$3.72

Annual Revenue

$10.96 M(+3565.22% YoY)

Annual EPS

-$0.62(+59.48% YoY)

Annual ROE

-23.16%

Beta

0.12

Events Calendar

Earnings

Next earnings date:

Apr 4, 2025

Recent quarterly earnings:

Nov 27, 2024

Recent annual earnings:

Apr 4, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 1, 2016

Analyst ratings

Recent major analysts updates

Feb 4, 25 D. Boral Capital
Buy
Nov 29, 24 HC Wainwright & Co.
Buy
Nov 27, 24 D. Boral Capital
Buy
Aug 21, 24 HC Wainwright & Co.
Buy
Aug 20, 24 EF Hutton
Buy
Aug 5, 24 EF Hutton
Buy
May 30, 24 HC Wainwright & Co.
Buy
Apr 5, 24 HC Wainwright & Co.
Buy
Nov 30, 23 HC Wainwright & Co.
Buy
Aug 25, 23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript
CLGN
seekingalpha.comNovember 27, 2024

CollPlant Biotechnologies Ltd (NASDAQ:CLGN ) Q3 2024 Earnings Conference Call November 27, 2024 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Operator Greetings, and welcome to the CollPlant Biotechnologies Third Quarter 2024 Earnings Call. At this time all participants are in a listen-only mode.

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CLGN
prnewswire.comNovember 27, 2024

- Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -Innovative breast implant technology designed to address a $3.0 billion market opportunity -Cash and cash equivalents balance as of September 30, 2024 was $15.4 million -Conference call to be held today at 10:00 a.m. U.S. EDT – REHOVOT, Israel , Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the third quarter ending September 30, 2024, and provided a corporate update.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CLGN
prnewswire.comNovember 12, 2024

- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel , Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets.

CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
CLGN
zacks.comAugust 21, 2024

CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.

CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript
CLGN
seekingalpha.comAugust 20, 2024

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2024 Earnings Conference Call August 20, 2024 10:00 AM ET Company Participants Dan Ferry - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Sean Lee - H.C.

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CLGN
prnewswire.comAugust 20, 2024

- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin ® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.

CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
CLGN
prnewswire.comJune 6, 2024

Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025 REHOVOT, Israel , June 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks.

CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
CLGN
prnewswire.comMay 29, 2024

Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time (details herein) REHOVOT, Israel , May 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CLGN
prnewswire.comMay 16, 2024

A conference call is scheduled for Wednesday, May 29, 2024 at 10:00 a.m. U.S. EDT. CollPlant Biotechnologies will release financial results for the first quarter of 2024 on the same day before the opening of the U.S. financial markets.

CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript
CLGN
Seeking AlphaApril 4, 2024

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2023 Earnings Conference Call April 4, 2024 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for CollPlant Biotechnologies?
  • Does CollPlant Biotechnologies pay dividends?
  • What sector is CollPlant Biotechnologies in?
  • What industry is CollPlant Biotechnologies in?
  • What country is CollPlant Biotechnologies based in?
  • When did CollPlant Biotechnologies go public?
  • Is CollPlant Biotechnologies in the S&P 500?
  • Is CollPlant Biotechnologies in the NASDAQ 100?
  • Is CollPlant Biotechnologies in the Dow Jones?
  • When was CollPlant Biotechnologies's last earnings report?
  • When does CollPlant Biotechnologies report earnings?
  • Should I buy CollPlant Biotechnologies stock now?

What is the ticker symbol for CollPlant Biotechnologies?

The ticker symbol for CollPlant Biotechnologies is NASDAQ:CLGN

Does CollPlant Biotechnologies pay dividends?

No, CollPlant Biotechnologies does not pay dividends

What sector is CollPlant Biotechnologies in?

CollPlant Biotechnologies is in the Healthcare sector

What industry is CollPlant Biotechnologies in?

CollPlant Biotechnologies is in the Biotechnology industry

What country is CollPlant Biotechnologies based in?

CollPlant Biotechnologies is headquartered in Israel

When did CollPlant Biotechnologies go public?

CollPlant Biotechnologies's initial public offering (IPO) was on January 31, 2018

Is CollPlant Biotechnologies in the S&P 500?

No, CollPlant Biotechnologies is not included in the S&P 500 index

Is CollPlant Biotechnologies in the NASDAQ 100?

No, CollPlant Biotechnologies is not included in the NASDAQ 100 index

Is CollPlant Biotechnologies in the Dow Jones?

No, CollPlant Biotechnologies is not included in the Dow Jones index

When was CollPlant Biotechnologies's last earnings report?

CollPlant Biotechnologies's most recent earnings report was on Nov 27, 2024

When does CollPlant Biotechnologies report earnings?

The next expected earnings date for CollPlant Biotechnologies is Apr 4, 2025

Should I buy CollPlant Biotechnologies stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions